September 18, 2026

SI-BONE, Inc. (SIBN) Investor Outlook: Exploring a 38% Potential Upside in the Healthcare Sector

SI-BONE, Inc. (NASDAQ: SIBN), a prominent player in the medical devices industry, is capturing investor attention with notable potential upside as indicated by recent analyst ratings...

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Exploring a 304% Potential Upside

Niagen Bioscience, Inc. (NAGE), a key player in the Consumer Defensive sector, specifically within the Packaged Foods industry, presents a unique investment opportunity with a staggering..

HealthStream, Inc. (HSTM) Stock Analysis: Evaluating an 18% Upside Potential in Healthcare Services

HealthStream, Inc. (NASDAQ: HSTM) stands as a pivotal player in the health information services industry, offering innovative Software-as-a-Service (SaaS) solutions tailored to meet the diverse needs..

CorMedix Inc. (CRMD) Stock Analysis: Biotech Innovator with a 97.69% Potential Upside

CorMedix Inc. (NASDAQ: CRMD) is capturing investor attention in the biotechnology sector with a significant potential upside of 97.69%, according to analyst ratings. This Parsippany, New..

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX), a key player in the biotechnology industry, is gaining attention from investors thanks to its promising product pipeline and remarkable potential..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating a 4.61% Potential Upside with Strategic Staffing Solutions

As investors navigate the ever-evolving landscape of healthcare investments, AMN Healthcare Services Inc. (NYSE: AMN) presents an intriguing opportunity within the medical care facilities industry. Based..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Biotechnology Innovator with an 85% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company specializing in the treatment of chronic cough associated with idiopathic pulmonary fibrosis (IPF) and other interstitial lung..

Spyre Therapeutics, Inc. (SYRE) Investor Outlook: A Biotech Stock with a Potential 29.56% Upside

For investors seeking dynamic opportunities in the biotechnology sector, Spyre Therapeutics, Inc. (NASDAQ: SYRE) stands out with a compelling narrative. With its market capitalization reaching $8.05..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotech Innovator with a 47% Upside Potential

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a trailblazer in the biotechnology sector, has captured investor attention with its promising pipeline and a robust 47.09% potential upside. As..

Nuvation Bio Inc. (NUVB): Investor Outlook with a 115.82% Potential Upside

Nuvation Bio Inc. (NUVB), a promising player in the biotechnology sector, presents a compelling opportunity for investors seeking exposure to innovative cancer therapies. With a market..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: A Biotech Gem with a 33% Upside Potential

Nurix Therapeutics, Inc. (NRIX) is making waves in the biotechnology sector, particularly for investors seeking high-growth opportunities in the healthcare industry. With a market capitalization of..

Immunome, Inc. (IMNM) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology

Investors eyeing the biotechnology sector may find Immunome, Inc. (NASDAQ: IMNM) an intriguing prospect. With a substantial market capitalization of $2.72 billion, Immunome is making waves..

Bicara Therapeutics Inc. (BCAX) Investor Outlook: Analyzing a 52.89% Potential Upside in the Biotech Sector

Investors with a keen eye on the biotechnology sector will find Bicara Therapeutics Inc. (NASDAQ: BCAX) to be a compelling prospect. This clinical-stage biopharmaceutical company, based..

InMode Ltd. (INMD) Stock Analysis: Unveiling the Growth Potential in the Medical Devices Sector

InMode Ltd. (NASDAQ: INMD) presents itself as a compelling player within the healthcare sector, focusing on the niche but rapidly growing industry of medical devices. Headquartered..

Pharvaris N.V. (PHVS) Stock Analysis: Biotech Innovator with a 53.58% Potential Upside

Pharvaris N.V. (PHVS) is emerging as a compelling opportunity within the biotechnology sector, attracting considerable investor attention thanks to its significant potential upside of 53.58%. The..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 159.98% Potential Upside in the Biotech Sector

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a notable player in the biotechnology sector, is capturing investor attention with its remarkable potential upside of 159.98%. With a market..

Physitrack expands its role in physical therapy software workflows

Physitrack is building its role as a digital rehabilitation layer that works alongside the EMR systems already used by physical therapy practices...

Oriole Resources sells Muratdere royalty for US$1.2 million

Oriole Resources has agreed to sell its 1.2% Net Smelter Return royalty in the Muratdere project in Turkey to Ardent Metals for US$1.2 million, with the..

Volta Finance declares €0.135 quarterly dividend

Volta Finance Limited has declared a quarterly interim dividend of €0.135 per share, payable on 29 October 2026. Shareholders may elect to receive the dividend in..
Search

Funds

September 18, 2026

Physitrack expands its role in physical therapy software workflows

Physitrack is building its role as a digital rehabilitation layer that works alongside the EMR systems already used by physical therapy practices...

Oriole Resources sells Muratdere royalty for US$1.2 million

Oriole Resources has agreed to sell its 1.2% Net Smelter Return royalty in the Muratdere project in Turkey to Ardent Metals for US$1.2 million, with the proceeds supporting the company’s activities in Cameroon...

Volta Finance declares €0.135 quarterly dividend

Volta Finance Limited has declared a quarterly interim dividend of €0.135 per share, payable on 29 October 2026. Shareholders may elect to receive the dividend in euros or pounds sterling, with currency elections due by 12 October 2026...
Search

Funds

September 18, 2026

FTSE 100

Funds